ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0532

Factors Associated with Cause-specific Discontinuation of Long-term Anti-tumor Necrosis Factor Agent Use in Patients with Ankylosing Spondylitis

bora nam1, Nayeon Choi2, Bon San Koo3, Jiyeong Kim2, Ji-Hui Shin1, Seunghun lee4, kyung bin Joo4 and Tae-Hwan Kim1, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea, 3Inje University Seoul Paik Hospital, Seoul, South Korea, 4Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

Meeting: ACR Convergence 2023

Keywords: Ankylosing spondylitis (AS), Anti-TNF Drugs, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0510–0542) Spondyloarthritis Including Psoriatic Arthritis – Treatment: AxSpA Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-tumor necrosis factor (TNF) agents have proven to be effective in treating Ankylosing spondylitis (AS). However, a significant number of patients discontinue or switch their anti-TNF agent for various reasons. Previous studies have been limited in scope, primarily focusing on drug retention rates or utilizing cohorts with short follow-up durations. The objective of this study is to investigate the factors associated with cause-specific discontinuation of long-term anti-TNF agent use in patients with AS.

Methods: AS patients who initiated the first-line anti-TNF agent between 2004 and 2018 and continued the treatment for at least 2 years were enrolled in the study. Patients with concomitant inflammatory bowel disease were excluded. The index date was defined as the date of initiation of the first-line anti-TNF agent, and the observation period lasted until the last visit, discontinuation of the first-line anti-TNF agent, or September 2022. The reasons for discontinuation of the first-line anti-TNF agent were categorized into 1) clinical remission, 2) lack of efficacy, 3) adverse events, and 4) other reasons including loss to follow-up, cost, or reimbursement issues. The cumulative incidence function curve was used to visualize the cumulative failure rates over time for each specific reason. Univariate and multivariate cause-specific hazard models were utilized to identify factors associated with cause-specific discontinuation of the first-line anti-TNF agent.

Results: A total of 429 AS patients were included in the study, with 121 on adalimumab (ADA), 176 on etanercept (ETN), 89 on infliximab (INF), and 43 on golimumab (GLM). The median overall survival on the first-line anti-TNF agent was 10.6 (7.9-14.5) years. Among the patients, 103 (24.0%) discontinued the first-line anti-TNF agent, with 36 (34.9%) due to inefficacy, 31 (30.1%) due to sustained clinical remission, 15 (14.6%) due to adverse events, and 21 (20.4%) due to other reasons. Patients treated with ETN had a lower risk of discontinuation due to sustained clinical remission compared to those on ADA (Hazard ratio [HR] 0.45 [0.21-0.99], P=0.048). Higher baseline BASDAI (HR 1.31 [1.04-1.65], P=0.023) and use of INF were associated with a higher likelihood of discontinuation due to inefficacy compared to ADA (HR 4.53 [1.45-14.16], P=0.009). Older age was related to an increased risk of discontinuation due to infection-related adverse events (HR 1.07 [1.02-1.12], P=0.005), and current smoking was a risk factor for discontinuation due to other reasons (HR 6.22 [1.82-21.28], P=0.004).

Conclusion: Several factors influencing cause-specific discontinuation of long-term anti-TNF treatment were identified in our study. Further investigation is needed to understand the underlying reasons for these phenomena. This knowledge is valuable for improving personalized medicine in the management of patients with AS, as it allows for more informed decision-making and the customization of treatment plans based on individual patient characteristics.

Supporting image 1

Figure 1. Cumulative incidence function according to anti-TNF agents

Supporting image 2

Table 1. Multivariable cause-specific hazard model for discontinuation of long-term anti-TNF agent use in AS patients


Disclosures: b. nam: None; N. Choi: None; B. Koo: None; J. Kim: None; J. Shin: None; S. lee: None; k. Joo: None; T. Kim: None.

To cite this abstract in AMA style:

nam b, Choi N, Koo B, Kim J, Shin J, lee S, Joo k, Kim T. Factors Associated with Cause-specific Discontinuation of Long-term Anti-tumor Necrosis Factor Agent Use in Patients with Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/factors-associated-with-cause-specific-discontinuation-of-long-term-anti-tumor-necrosis-factor-agent-use-in-patients-with-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-cause-specific-discontinuation-of-long-term-anti-tumor-necrosis-factor-agent-use-in-patients-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology